Dr. Sanjay Roy, Professor, AIIMS Center for Community Medicine, informed that the selection process for the clinical trial of the vaccine on children aged 8 to 12 years will start today.
The country’s first indigenously developed first anti-covid vaccine, covacin, will begin this month for enrollment in clinical trials for children aged six to 12 years. This will be followed by a clinical examination of children aged two to six years. The process of enrollment of volunteers aged 12-16 years in the All India Institute of Medical Sciences (AIIMS) has been completed and they have been given the first dose of covacin.
“The selection process for clinical trials of the vaccine on children aged six to 12 will begin on Tuesday,” said Dr Sanjay Roy, a professor at the AIIMS Center for Community Medicine. On May 12, the Directorate General of Drug Control in India (DCGI) approved the second and third phase clinical trials of a biotech covaxin from India among children aged two to 18 years.
It has to be tested in three parts
The test will be conducted in three sections consisting of three groups of 175-165 volunteers aged 12-16, 6-12, and 2-6 years. During the trial, two doses of the vaccine will be given intramuscularly, the second on the 28th day of the first dose. The vaccine has been manufactured indigenously by Biotech India in collaboration with the Indian Council of Medical Research (ICMR) and is currently being given to adults during an ongoing vaccination campaign across the country.
Worry about the effect on the child
Clinical trials will assess the safety, reactivity, and immunity of the child’s vaccine. The government had recently warned that Covid-19 has not yet had a serious impact on children, but if the behavior of the virus or the dynamics of epidemiology changes, the impact on children could increase. Readiness to deal with any situation has been strengthened.
(Disclaimer: This news is published directly from Syndicate Feed.)